Gastro Intestinal Cancers are a major cause of deaths:

Colorectal and Pancreatic cancers are estimated to cause nearly 400,000 deaths annually across the USA, the UK, France, Germany, Spain, Italy and Japan, representing a major medical need.

How do we solve this?

Antelope has identified CA242, a highly prevalent target across both tumor types that is absent from healthy tissue.To address this target, Antelope has developed ATL-024, an ADC that combines a clinically de-risked antibody, a proprietary linker platform, and a topoisomerase I inhibitor payload.In preclinical studies, ATL-024 has demonstrated a compelling efficacy and outstanding NHP tolerability.

Targeting clinical entry in 2027, Antelope is seeking strategic partners to accelerate the development of ATL-024.

Get in touch with Antelope's team at [email protected]